Holen Sie sich die Stockscreener-App
0.9825
4.49%
0.0422
Inflarx N V Aktie (IFRX) Neueste Nachrichten
Treasury Yields: Can InflaRx NV sustain earnings growth2026 Earnings Surprises & Daily Stock Momentum Reports - baoquankhu1.vn
Can InflaRx's Vilobelimab Stage A Revival In Pyoderma Gangrenosum? - RTTNews
HC Wainwright Forecasts InflaRx's Q3 Earnings (NASDAQ:IFRX) - MarketBeat
Analyst Upgrade: Is InflaRx NV a top pick in the sector2026 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Aug Shorts: Can InflaRx NV sustain earnings growthMarket Movement Recap & Community Trade Idea Sharing - baoquankhu1.vn
Bear Alert: Is InflaRx NV a top pick in the sector2026 Gainers & Daily Momentum Trading Reports - baoquankhu1.vn
InflaRx NV (IFRX) reports Q4 loss, lags revenue estimates - MSN
Raymond James raises Inflarx stock price target on drug trial data - Investing.com India
InflaRx Survival Hopes Rest On Izicopan - Citeline News & Insights
InflaRx (NASDAQ:IFRX) Given New $14.00 Price Target at Guggenheim - MarketBeat
Guggenheim cuts Inflarx stock price target on model update to $14 - Investing.com Canada
Guggenheim cuts Inflarx stock price target on model update to $14 By Investing.com - Investing.com Australia
Q1 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat
InflaRx (IFRX) posts 2025 loss, relies on cash runway and grants - Stock Titan
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
InflaRx NV reports results for the quarter ended December 31Earnings Summary - TradingView
IFRX: Izicopan's promising Phase 2a data drives strategic focus and extends cash runway to mid-2027 - TradingView
InflaRx (NASDAQ:IFRX) Issues Earnings Results, Meets Expectations - MarketBeat
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027 - TipRanks
Inflarx reports full year 2025 results and highlights key achievements and expected milestones - marketscreener.com
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones - The Manila Times
InflaRx (IFRX) narrows 2025 loss, shifts focus to izicopan growth - Stock Titan
IFRX: Izicopan advances as the lead asset with strong Phase 2a data, cost cuts, and extended cash runway - TradingView
InflaRx N.V. (IFRX) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
InflaRx to present Phase 3 pyoderma gangrenosum data at AAD By Investing.com - Investing.com South Africa
InflaRx FY 2025 earnings preview - MSN
Aug Opening: Is InflaRx NV forming bullish engulfing patterns2026 PreEarnings & Precise Buy Zone Tips - baoquankhu1.vn
Aug Levels: Can InflaRx NV outperform under higher oil prices2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
InflaRx (IFRX) director Mark Kubler reports 960,015 shares and multiple options - Stock Titan
InflaRx (IFRX) director lists options and 10,000 Ordinary Shares - Stock Titan
InflaRx (IFRX) director Brudnick reports shares and multiple stock option grants - Stock Titan
InflaRx (IFRX) director details vested and future stock options - Stock Titan
InflaRx (IFRX) CSO discloses 1.76M shares and multiple option grants - Stock Titan
InflaRx (IFRX) officer discloses vested and performance stock options - Stock Titan
InflaRx (IFRX) director discloses sizeable share and option stakes - Stock Titan
InflaRx (IFRX) CEO reports 1,068,908 shares plus option grants - Stock Titan
InflaRx (IFRX) CFO details extensive stock option and share holdings - Stock Titan
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting - The Manila Times
InflaRx N.V. to Present Phase 3 Study Data on Vilobelimab for Pyoderma Gangrenosum at AAD 2026 Annual Meeting - Quiver Quantitative
Vilobelimab Phase 3 data earns late-breaker slot at AAD 2026 meeting - Stock Titan
InflaRx NV expected to post a loss of 15 cents a shareEarnings Preview - TradingView
InflaRx (IFRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
InflaRx receives Nasdaq notification - MSN
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Sahm
InflaRx receives Nasdaq notice over minimum bid price rule By Investing.com - Investing.com South Africa
InflaRx Receives Nasdaq Deficiency Notice Over Minimum Bid Price - National Today
InflaRx (IFRX) hit with Nasdaq minimum $1 bid-price warning and cure window - Stock Titan
InflaRx receives Nasdaq notice over minimum bid price rule - Investing.com
InflaRx to Report Full Year 2025 Results on March 19, 2026 - Sahm
InflaRx (IFRX) to Release Earnings on Thursday - MarketBeat
IFRX: Izicopan advances as a lead asset with strong HS data, new indications, and global expansion plans - TradingView
Breakout Move: Can InflaRx N.V. stock maintain growth trajectoryWeekly Trend Report & Growth Focused Stock Reports - Naître et grandir
Market Leaders: Is InflaRx NV a top pick in the sectorGap Down & Weekly Stock Performance Updates - baoquankhu1.vn
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):